Fortrea sees intensifying competition in obesity drug market
FTRE•Fortrea’s analysis points to intensifying competition as next-generation obesity therapies raise efficacy expectations. Retatrutide delivered mean weight reductions approaching 30% in some Phase III populations, and publicly announced timelines suggest regulatory submissions may occur in 2027.
1. Competition and treatment goals
Fortrea’s analysis says next-generation obesity therapies are raising efficacy expectations, with retatrutide delivering mean weight reductions approaching 30% in some Phase III populations. Publicly announced timelines suggest regulatory submissions may occur in 2027. High first-year treatment discontinuation makes long-term persistence a development priority, while tolerability, costs and reimbursement restrictions remain barriers; future therapies are expected to compete on sustained weight management, lean-mass preservation and broader health benefits.
